A double-blind, randomized, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm

Carlos R M Rieder, Pedro Schestatsky, Mariana P Socal, Thaís Lampert Monte, Daniele Fricke, João Costa, Paulo Dornelles Picon

Research output: Contribution to journalArticle


There is a lack of evidence on the clinical efficacy and safety of the recently released Chinese botulinum toxin serotype A (Prosigne) for the treatment of focal dystonias and hemifacial spasm. Determining a more precise role of Prosigne in the treatment of such conditions is of paramount importance, because botulinum toxin type A treatments have a huge economic implication in health services, especially in developing countries. The aim of our study was to compare the efficacy and safety of Prosigne in the treatment of blepharospasm and hemifacial spasm in comparison to Botox. We performed a double-blind, randomized, crossover study enrolling 26 patients. There were no significant differences between Prosigne and Botox regarding subjective global improvement, response onset, efficacy duration, and incidence and severity of adverse events. Our results suggest that Prosigne and Botox are comparable with respect to efficacy and safety for the short-term treatment of blepharospasm and hemifacial spasm.

Original languageEnglish (US)
Pages (from-to)39-42
Number of pages4
JournalClinical Neuropharmacology
Issue number1
Publication statusPublished - Jan 2007
Externally publishedYes



  • Blepharospasm
  • Botulinum toxin type A
  • Hemifacial spasm
  • Randomized clinical trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this